NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

Healzen Therapeutics Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase ...

Merck KGaA has reported proteolysis targeting chimera (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; ...

About Arvinas Inc. Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing protein ...